CAMPATH vs ONCASPAR

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 21, 2026·How we rate

Possible drug interaction. CAMPATH and ONCASPAR are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	CAMPATH	ONCASPAR
Rating	70/100	New
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	ALEMTUZUMAB	PEGASPARGASE
Manufacturer	Genzyme	Sigma Tau
Dosage forms	Injectable	Injectable
Drug class	Cd52-Directed Cytolytic Antibody	—
Boxed warning	Boxed warning	None
Treats	B-Cell Chronic Lymphocytic Leukemia	Blast Crisis, Non-Hodgkin Lymphoma, B-Cell Chronic Lymphocytic Leukemia

campath oncaspar

Rating

70/100

New

Pharmacy pays

—

Type

Active ingredient

ALEMTUZUMAB

PEGASPARGASE

Manufacturer

Genzyme

Sigma Tau

Dosage forms

Injectable

Drug class

Cd52-Directed Cytolytic Antibody

—

Boxed warning

None

Treats

B-Cell Chronic Lymphocytic Leukemia

Blast Crisis, Non-Hodgkin Lymphoma, B-Cell Chronic Lymphocytic Leukemia

Frequently asked questions

What is the difference between Campath and Oncaspar?

Campath contains Alemtuzumab, while Oncaspar contains Pegaspargase — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.